The 2019 ISPE Aseptic Conference focuses on the future of aseptic processing, including containment, multi-product facilities, and the increasing use of robotics.
|Opens||25 June 2018|
|Deadline||03 August 2018|
|Review||21 June - 03 August 2018|
|Notification||By 17 August 2018|
By submitting a proposal, you acknowledge that, if your proposal is accepted, your organization will support your attendance at the conference. Accepted Presenters are responsible for their own travel and accommodations and receive complimentary registration for the conference. Session Leaders and panelists (not also presenting as a speaker), co-presenters, and poster presenters are eligible for a 20% discount to the prevailing rate and your membership status at the time of registration.
The pharmaceutical industry must identify and drive emerging trends in new technology. We’re looking for case studies about technologies such as “lights-out” processing, gloveless isolators, closed-system processing, advanced on-line monitoring, rapid-microbiological monitoring, and pulsed-light decontamination. We’re also looking for companies the use automated, clean-in-place isolators to enable multi-product flexibility for toxic/ high-potency materials.
Single use systems in the pharmaceutical industry offer a lot of advantages: no material prep and sterilization on site, off-the-shelf solutions, and reduced capital investment. At the same time, per batch cost of goods increases, and maintaining reliable supply with vendors and their changes can be challenging. Leachables and extractables, particles, leaks and integrity can also become bigger issues. Submit a case study/presentation sharing your knowledge and experience implementing single-use systems.
Building flexibility into new facilities is key to optimal operational usage. Submit a case study/presentation where flexibility was included early in the design phase, allowing for seamless transitions for evolving requirements. The best flexible lines include provisions to run different products in different presentations on the same line. To achieve this, quick change-over procedures, including measures to avoid cross-contamination, need to be in place. We’re looking for examples of facilities where this strategy has been successfully implemented and approved by regulatory authorities.
The Survey on Aging Facilities conducted by ISPE in 2018 showed that many facilities are falling behind in upgrading to current aseptic standards and regulatory expectations. Upgrades and renovations, while keeping the facilities in operation are possible. Submit a case study of a successfully executed upgrade. Examples of such upgrades may include retrofit of a conventional filling line to a RABS filling line. We’re also looking for the regulatory filing aspects of these upgrades.
Inspired by the advancement of robotics in other industries, the pharma industry is beginning to challenge the traditional aseptic model with an ideal goal of zero operator intervention in the aseptic filling/stoppering process. Robots can be used to minimize manual glove port manipulations and reduce both the amount and the complexity of equipment. They offer full flexibility for various packaging types with rapid format change and ensure accurate and clean container handling. Above all, robotic systems can be adapted to meet evolving pharma industry requirements. We’re looking for case studies of successfully implemented robotic technology to reduce human intervention.
Many drivers in the pharmaceutical industry are pushing manufacturing operations toward smaller batches, including personalized/ individualized/ stratified medicine, including cell and gene therapies. Beginning now and growing in the future, one batch may be one vial/ bag for one patient. This strong trend raises questions and brings new challenges: how to test and release a “batch” of one container? How to validate a “batch” of one container? Sterility assurance? Supply chain? Submit your real-world case studies in this evolving area.
By the year 2025 every second new Biopharmaceutical product will be considered highly potent and/or toxic with the oncology sector driving the growth. New combination products like ADC`s “Antibody Drug Conjugates”, Gene and Cell Therapy create more stringent requirements for cleaning in multi-product facilities to prevent cross contamination and provide occupational safety for the operators. Share your experience with multi-product facilities with potent/toxic products.